Abstract
The efficacy of metronomic chemotherapy — the continuous administration of cytotoxic agents at low doses — might largely be mediated by its antiangiogenic activity. A cytotoxic effect on endothelial cells might be involved in this process. We report herein the major efficacy and excellent tolerance of low-dose cyclophosphamide and methotrexate in a 51-year-old metastatic breast cancer patient presenting with diffuse liver involvement and icterus. Given as first- or second-line treatment in metastatic breast cancer, metronomic chemotherapy has demonstrated clinical activity and represents an alternative in patients when conventional regimens are contraindicated.
Résumé
L’activité antiangiogénique des traitements cytotoxiques conventionnels, ici le méthotrexate et le cyclophosphamide, peut être obtenue en administrant de faibles doses de chimiothérapie, de façon continue. C’est le principe de la chimiothérapie métronomique. Ce schéma permet un blocage continu de l’angiogenèse tumorale par action sur les cellules endothéliales. À travers le cas d’une patiente atteinte d’un cancer de sein métastatique, on expose l’efficacité de ce traitement sur la maladie néoplasique ainsi que son excellente tolérance. II permet le traitement de patientes non candidates à un traitement conventionnel lorsque celui-ci est contre-indiqué, comme chez cette patiente atteinte d’un envahissement hépatique métastatique massif avec ictère, ainsi que le maintien d’une qualité de vie correcte avec des toxicités faibles ou nulles. Administré de manière précoce dans la maladie métastatique, en première ou deuxième ligne, ce traitement donne demeilleurs résultats en termes de survie sans progression que s’il est administré plus tardivement.
Similar content being viewed by others
Bibliographie
Browder T, Butterfield CE, Kräling BM (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60(7): 1878–1886
Colleoni M, Rocca A, Sandri MT, et al. (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13(1): 73–80
Dellapasqua S, Bertolini F, Bagnardi V, et al. (2008) Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 26(30): 4899–4905
Denekamp J (2000) Vascular attack as a therapeutic stategy. Cancer Metastasis Rev 9(3): 267–282
Hahnfeldt P, Folkman J, Hlatky L (2003) Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J Theor Biol 220(4): 545–554
Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8): 1045–1047. No abstract available
Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3): 353–364
Kerbel RS, Kamen BA (2004) The antiangiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4(6): 423–436. Review
Klement G, Huang P, Mayer B, et al. (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 8(1): 221–232
Lord R, Nair S, Schache A, et al. (2007) Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study. J Urol 177(6): 2136–2140. Discussion 2140
Mancuso P, Colleoni M, Calleri A, et al. (2006) Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 108(2): 452–459. Epub 2006 Mar 16
Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19(4): 1195–1206. Review
Orlando L, Cardillo A, Rocca A, et al. (2006) Prolonged clinical benefit with metronomic chemotherapy in patients with metastatic breast cancer. Anticancer Drugs 17(8): 961–967
Sandri MT, Johansson HA, Zorzino L (2007) Serum EGFR and serum HER2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 110(3): 509–517
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Gaumier, A., Hamizi, S., You, B. et al. La chimiothérapie métronomique du cancer du sein métastatique: à propos d’un cas. Oncologie 12, 436–439 (2010). https://doi.org/10.1007/s10269-010-1912-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10269-010-1912-9